Miproxifene
Miproxifene[edit | edit source]
Miproxifene is a selective estrogen receptor modulator (SERM) that was developed for the treatment of breast cancer. It is a nonsteroidal compound that exhibits both estrogenic and antiestrogenic properties depending on the target tissue. Miproxifene is structurally related to other SERMs such as tamoxifen and raloxifene.
Mechanism of Action[edit | edit source]
Miproxifene functions by binding to estrogen receptors (ERs) in various tissues. It acts as an estrogen receptor antagonist in breast tissue, which helps to inhibit the proliferation of estrogen receptor-positive breast cancer cells. In other tissues, such as bone and the cardiovascular system, miproxifene may exhibit partial agonist activity, which can be beneficial in maintaining bone density and cardiovascular health.
Development and Clinical Trials[edit | edit source]
Miproxifene was developed as a potential therapeutic agent for breast cancer due to its ability to selectively modulate estrogen receptor activity. Clinical trials were conducted to evaluate its efficacy and safety profile. However, despite promising preclinical data, miproxifene did not advance to market approval due to various factors, including competition from other more established SERMs and the results of clinical trials.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of miproxifene includes its absorption, distribution, metabolism, and excretion. Miproxifene is administered orally and undergoes hepatic metabolism. The metabolites of miproxifene contribute to its pharmacological activity, similar to other SERMs.
Potential Applications[edit | edit source]
While primarily investigated for breast cancer treatment, miproxifene's SERM properties suggest potential applications in other conditions influenced by estrogen receptor modulation. These may include osteoporosis and cardiovascular disease, where estrogen plays a protective role.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
